Clinical Trial Update: Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for SC10914 in patients with gBRCA1/2-mutated advanced ovarian cancer is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• SC10914

Snippet

Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Conditions: Advanced Ovarian Cancer | Phase 2 | Status: UNKNOWN